# Study of Neoadjuvant CT With Selective Radiotherapy in Patients With Intermediate-Risk Cancer Rectum

> **NCT00909987** · PHASE2 · COMPLETED · sponsor: **Grupo Espanol Multidisciplinario del Cancer Digestivo** · enrollment: 46 (actual)

## Conditions studied

- Rectum Cancer

## Interventions

- **DRUG:** Capecitabine
- **DRUG:** Oxaliplatin
- **DRUG:** Bevacizumab
- **RADIATION:** Radiotherapy
- **DRUG:** Capecitabine during all Radiotherapy period
- **PROCEDURE:** Total Mesorectal Excision (TME)

## Key facts

- **NCT ID:** NCT00909987
- **Lead sponsor:** Grupo Espanol Multidisciplinario del Cancer Digestivo
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2013-01
- **Final completion:** 2013-06
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2013-10-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00909987

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00909987, "Study of Neoadjuvant CT With Selective Radiotherapy in Patients With Intermediate-Risk Cancer Rectum". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00909987. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*